Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
115 hedge funds and large institutions have $99.9M invested in Provention Bio, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 19 closing their positions.
276% more call options, than puts
Call options by funds: $3.17M | Put options by funds: $842K
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
2% more funds holding
Funds holding: 113 → 115 (+2)
43% less capital invested
Capital invested by funds: $176M → $99.9M (-$76.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$2.81M |
| 2 |
BlackRock
New York
|
+$1.02M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$904K |
| 4 |
Renaissance Technologies
New York
|
+$790K |
| 5 |
DCM
DG Capital Management
New York
|
+$474K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$3.23M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$964K |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$598K |
| 4 |
Nisa Investment Advisors
St. Louis,
Missouri
|
-$332K |
| 5 |
AI
Atom Investors
Austin,
Texas
|
-$312K |
PRVB Hedge Fund Activity: Q2 2022 in Review
115 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q2 2022, worth a combined $99.9M — down 43% from $176M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PRVB positions and 19 closed out — a net gain of 5 holders — while 32 added to existing stakes and 28 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $2.81M. The largest seller was Perceptive Advisors, cutting an estimated $3.23M.
- 115 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q2 2022, up from 113 in Q1 2022.
- Funds reported $99.9M of Provention Bio, Inc. Common Stock stock for Q2 2022, down 43% quarter-over-quarter.
- 24 funds opened new Provention Bio, Inc. Common Stock positions in Q2 2022 and 19 closed out, a net change of +5 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q2 2022 was MPM BioImpact, an estimated $2.81M added.
- The largest Provention Bio, Inc. Common Stock seller in Q2 2022 was Perceptive Advisors, an estimated $3.23M sold.
Based on aggregated 13F filings for Q2 2022.